Ezetimibe & Rosuvastatin Interaction

Ezetimibe (Zetia) is a cholesterol absorption inhibitor that blocks intestinal uptake of dietary and biliary cholesterol. Rosuvastatin (Crestor) is an HMG-CoA reductase inhibitor (statin) that reduces hepatic cholesterol synthesis. These medications are frequently combined for enhanced LDL cholesterol lowering and are available as a fixed-dose combination product (Roszet).

The interaction between ezetimibe and rosuvastatin is pharmacokinetic in nature but clinically minor. Co-administration produces a modest increase in ezetimibe exposure without clinically meaningful changes in rosuvastatin pharmacokinetics. The combination is widely endorsed by cardiovascular guidelines for patients who do not achieve LDL goals on statin monotherapy.

The IMPROVE-IT trial provided landmark evidence that adding ezetimibe to statin therapy reduces cardiovascular events, establishing the clinical value of this combination approach.

Ezetimibe is absorbed in the small intestine and undergoes extensive glucuronidation to ezetimibe-glucuronide, which is pharmacologically active. The drug participates in enterohepatic recirculation, contributing to its sustained cholesterol-lowering effect. Ezetimibe does not significantly interact with CYP450 enzymes.

Rosuvastatin is minimally metabolized, with approximately 10% undergoing CYP2C9-mediated metabolism. It is primarily eliminated unchanged via biliary excretion and renal excretion. Co-administration of rosuvastatin with ezetimibe increases ezetimibe AUC by approximately 18-20%, likely through effects on intestinal transporters. This modest pharmacokinetic change is not considered clinically significant.

The clinical significance of the pharmacokinetic interaction is low. The modest increase in ezetimibe exposure does not produce meaningful increases in adverse effects. Clinical trials of the combination, including large outcomes trials, have demonstrated safety profiles comparable to the individual drugs.

The pharmacodynamic interaction is intentionally therapeutic. Ezetimibe and rosuvastatin reduce cholesterol through complementary mechanisms (absorption inhibition and synthesis inhibition), producing approximately 15-20% additional LDL reduction when combined compared to statin alone. This additive effect is the clinical rationale for the combination.

Rare cases of myopathy have been reported with the ezetimibe-statin combination, but the incremental risk attributable to ezetimibe appears minimal based on large clinical trial data.

Both medications can be used at their standard recommended doses without interaction-related dose adjustments. The fixed-dose combination product (Roszet) contains full doses of both drugs, confirming the safety of standard dosing.

Both medications can be taken together at the same time of day. While rosuvastatin can be taken at any time, evening dosing is traditionally preferred for statins, and ezetimibe is similarly flexible. Taking both together improves adherence.

Patients should be counseled that the combination provides additive cholesterol lowering and that both medications should be continued as prescribed. Lifestyle modifications (diet, exercise) remain important adjuncts to pharmacotherapy.

Lipid panel monitoring should follow standard guidelines: check at baseline, 4-12 weeks after initiation or dose change, and then every 3-12 months. CK levels do not require routine monitoring but should be checked if the patient reports muscle symptoms.

Liver function tests should be checked per statin monitoring guidelines. While routine periodic monitoring of transaminases is no longer universally recommended, baseline testing and repeat testing for clinical indications is prudent.